Effects of Somatostatin Analogs on Catecholamine Biosynthesis Regulated by Corticosteroids and Bone Morphogenetic Proteins in Rat Pheochromocytoma Cells

Regulatory roles of SSAs in catecholamine synthesis have not been elucidated. To clarify the actions of SSAs on catecholamine biosynthesis, we investigated the mutual interactions among SSAs including octreotide and pasireotide, steroids and BMPs using rat pheochromocytoma PC12 cells. Treatment with octreotide and pasireotide (10 nM to 10 μM) had no significant effect on mRNA levels of Th, DOPA decarboxylase and dopamine-β-hydroxylase in PC12 cells. Regarding the interaction with steroids, treatments with SSAs also had no effect on dexamethasone- or aldosterone-induced Th mRNA expression, while pasireotide reduced mRNA expression of the GR. As for the interaction with BMP-4, which can suppress Th mRNA expression by PC12 cells, SSAs did not affect Th expression reduced by BMP-4 and Id1 or Smad1/5/9 activation induced by BMP-4. However, BMP-4 treatment up-regulated MR expression, while treatment with noggin, which neutralizes endogenous BMPs, downregulated MR expression, and the presence of noggin also attenuated aldosterone-induced Th expression, suggesting that endogenous BMPs act to enhance MR activity. Moreover, BMP-4 treatment suppressed the expression of somatostatin receptors including Sstr2 and Sstr5 in PC12 cells, while treatment with noggin up-regulated the expression of Sstr2 and Sstr5, suggesting that BMPs play a desensitizing role in SSA actions. Collectively, the results revealed that SSAs have no direct effect on catecholamine synthesis; however, adrenomedullar BMPs could be modulators for the responsiveness to MR and SSTRs.

[1]  C. Haglund,et al.  Variable somatostatin receptor subtype expression in 151 primary pheochromocytomas and paragangliomas. , 2019, Human Pathology.

[2]  K. Takekoshi,et al.  Risk Stratification on Pheochromocytoma and Paraganglioma from Laboratory and Clinical Medicine , 2018, Journal of clinical medicine.

[3]  T. Matsuda,et al.  Efficacy and safety of metyrosine in pheochromocytoma/paraganglioma: a multi-center trial in Japan. , 2018, Endocrine journal.

[4]  G. Arnaldi,et al.  Long-term treatment of Cushing’s disease with pasireotide: 5-year results from an open-label extension study of a Phase III trial , 2017, Endocrine.

[5]  F. Otsuka,et al.  Melatonin regulates catecholamine biosynthesis by modulating bone morphogenetic protein and glucocorticoid actions , 2017, The Journal of Steroid Biochemistry and Molecular Biology.

[6]  F. Otsuka,et al.  BMP-6 modulates somatostatin effects on luteinizing hormone production by gonadrotrope cells , 2016, Peptides.

[7]  F. Beuschlein,et al.  Oncogenic features of the bone morphogenic protein 7 (BMP7) in pheochromocytoma , 2015, Oncotarget.

[8]  F. Otsuka,et al.  Regulatory role of BMP-9 in steroidogenesis by rat ovarian granulosa cells , 2015, The Journal of Steroid Biochemistry and Molecular Biology.

[9]  B. Glaser,et al.  Safety and efficacy of oral octreotide in acromegaly: results of a multicenter phase III trial. , 2015, The Journal of clinical endocrinology and metabolism.

[10]  K. Vrana,et al.  Complex molecular regulation of tyrosine hydroxylase , 2014, Journal of Neural Transmission.

[11]  F. Otsuka,et al.  Involvement of bone morphogenetic protein activity in somatostatin actions on ovarian steroidogenesis , 2013, The Journal of Steroid Biochemistry and Molecular Biology.

[12]  F. Otsuka,et al.  Activities of bone morphogenetic proteins in prolactin regulation by somatostatin analogs in rat pituitary GH3 cells , 2011, Molecular and Cellular Endocrinology.

[13]  F. Otsuka,et al.  Effects of bone morphogenetic protein (BMP) on adrenocorticotropin production by pituitary corticotrope cells: involvement of up-regulation of BMP receptor signaling by somatostatin analogs. , 2010, Endocrinology.

[14]  F. Otsuka.  Multiple endocrine regulation by bone morphogenetic protein system. , 2010, Endocrine journal.

[15]  C. Schade-Brittinger,et al.  Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  F. Otsuka,et al.  Enhancement of aldosterone-induced catecholamine production by bone morphogenetic protein-4 through activating Rho and SAPK/JNK pathway in adrenomedullar cells. , 2009, American journal of physiology. Endocrinology and metabolism.

[17]  G. Bellastella,et al.  Effects of somatostatin analog SOM230 on cell proliferation, apoptosis, and catecholamine levels in cultured pheochromocytoma cells. , 2008, Journal of molecular endocrinology.

[18]  L. David,et al.  Bone Morphogenetic Protein-9 Is a Circulating Vascular Quiescence Factor , 2008, Circulation research.

[19]  F. Otsuka,et al.  Regulatory roles of bone morphogenetic proteins and glucocorticoids in catecholamine production by rat pheochromocytoma cells. , 2005, Endocrinology.

[20]  S. Bornstein,et al.  Cortical-chromaffin cell interactions in the adrenal gland , 2005, Endocrine pathology.

[21]  H. Schmid,et al.  Functional Activity of the Multiligand Analog SOM230 at Human Recombinant Somatostatin Receptor Subtypes Supports Its Usefulness in Neuroendocrine Tumors , 2004, Neuroendocrinology.

[22]  D. L. Wong.  Why is the adrenal adrenergic? , 2003, Endocrine pathology.

[23]  E. Baudin,et al.  Effects of slow‐release octreotide on urinary metanephrine excretion and plasma chromogranin A and catecholamine levels in patients with malignant or recurrent phaeochromocytoma , 2002, Clinical endocrinology.

[24]  K. Takekoshi,et al.  Expression of mRNA coding for four catecholamine-synthesizing enzymes in human adrenal pheochromocytomas. , 1998, European journal of endocrinology.

[25]  A. Bockisch,et al.  Octreotide scintigraphy and catecholamine response to an octreotide challenge in malignant phaeochromocytoma , 1997, Clinical endocrinology.

[26]  L. Saltz,et al.  Acute hypertensive crisis following octreotide administration in a patient with malignant pheochromocytoma. , 1995, Oncology reports.

[27]  J. Bertherat,et al.  Molecular and pharmacological characterization of somatostatin receptor subtypes in adrenal, extraadrenal, and malignant pheochromocytomas. , 1995, The Journal of clinical endocrinology and metabolism.

[28]  C. Invitti,et al.  Effect of octreotide on catecholamine plasma levels in patients with chromaffin cell tumors. , 1993, Hormone research.

[29]  L. Kvols,et al.  Treatment of the malignant carcinoid syndrome. Evaluation of a long-acting somatostatin analogue. , 1986, The New England journal of medicine.

[30]  J. Byrd,et al.  Epinephrine synthesis in the PC12 pheochromocytoma cell line. , 1986, European journal of pharmacology.

[31]  A. Tischler,et al.  Glucocorticoids Increase Catecholamine Synthesis and Storage in PC 12 Pheochromocytoma Cell Cultures , 1983, Journal of neurochemistry.

[32]  H. Thoenen,et al.  Glucocorticoid induction of tyrosine hydroxylase in a continous cell line of rat pheochromocytoma , 1978, The Journal of cell biology.

[33]  L A Pohorecky,et al.  Adrenocortical control of the biosynthesis of epinephrine and proteins in the adrenal medulla. , 1972, Pharmacological reviews.

[34]  S. Udenfriend,et al.  TYROSINE HYDROXYLASE. THE INITIAL STEP IN NOREPINEPHRINE BIOSYNTHESIS. , 1964, The Journal of biological chemistry.